Wire · opportunities
Jazz's HER2 bispecific Ziihera gains FDA approval to change practice in stomach cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
Jazz Pharmaceuticals' bispecific antibody Ziihera has received FDA approval for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma, replacing trastuzumab as the standard HER2 agent and demonstrating a significant survival benefit in clinical trials.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 25 Aug 2026 and 31 Aug 2026.
◆ ◆ The Wire takeaway
The FDA approval of Ziihera resets treatment standards for HER2-positive stomach cancer, opening a key commercial opportunity to displace entrenched therapies. You need to re-evaluate partnerships and clinical priorities around HER2-targeted bispecifics this week.
◆ Coverage
2 sources · first reported 25 Aug 2026 · latest 31 Aug 2026
◆ Related on Wire
◆ Topics